Esmedulan, Zyke .
HRN: 22-93-24 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/17/2023
CEFUROXIME 750MG (VIAL)
04/17/2023
04/23/2023
IVT
300mg
Q12
Kawasaki Disease
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes